For the Inventor, By the Inventor

Enter assignee name

Houston, TX, United States of America

Io Therapeutics, Inc.

USPTO Granted Patents = 72

% Expired Patents = 8.3

CIPO Patents = 4

EPO Patents = 7

Forward Citations = 441

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Roshantha A Chandraratna (63 out of 291 patents)

Martin E Sanders (49 out of 51 patents)

Randolph J Noelle (11 out of 66 patents)

4. Ethan Dmitrovsky (11 out of 21 patents)

5. Elizabeth Nowak (11 out of 18 patents)

6. Vidyasagar Pradeep Vuligonda (7 out of 86 patents)

7. Powel H Brown (4 out of 4 patents)

8. Andrew S Thompson (2 out of 75 patents)

9. Gabriel Ghiaur (2 out of 2 patents)

10. Thomas Jacks (2 out of 2 patents)

11. Peter Wade (2 out of 2 patents)

12. Richard John Jones (2 out of 8 patents)

13. Shanming Kuang (2 out of 2 patents)

14. Harsh Shailesh Shah (2 out of 2 patents)

15. Cassandra Moyer (2 out of 2 patents)

Core Competencies:

RXR Agonists

Cancer Treatment

Autoimmune Disorders

Immunomodulatory Effects

Selective RXR Agonists

RAR Agonists

Nervous System Disorders

Polymorphs

Thyroid Hormones

Muscular Disorders

Drug Resistant Cancers

Synthetic Methods

72 patents: Sort by Forward Citations

1. 12383521 - Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists (2025-08-12),

2. 12325685 - RXR agonist salt form, polymorphs thereof, and uses thereof (2025-06-10),

3. 12115193 - Methods of using RARγ agonists for cancer treatment (2024-10-15),

4. 11998521 - Use of an RXR agonist in treating drug resistant HER2+ cancers (2024-06-04),

5. 11976021 - Synthesis of tetrahydronaphthalenols and uses thereof (2024-05-07),

6. 11919848 - RXR agonist salt form, polymorphs thereof, and uses thereof (2024-03-05),

7. 11896558 - Use of an RXR agonist and taxanes in treating Her2+ cancers (2024-02-13),

8. 11793835 - Methods of using RARγ agonists for cancer treatment (2023-10-24),

9. 11793781 - Autoimmune disorder treatment using RXR agonists (2023-10-24),

10. 11786555 - RAR selective agonists in combination with immune modulators for cancer immunotherapy (2023-10-17),

11. 11779558 - Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy (2023-10-10),

12. 11737996 - Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy (2023-08-29),

13. 11690832 - Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones (2023-07-04),

14. 11690831 - Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones (2023-07-04),

15. 11648223 - Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy (2023-05-16),

Company Overview

Io Therapeutics, Inc., based in Houston, TX, specializes in the development of RXR agonists aimed at addressing various health challenges. The company focuses on innovative treatments for cancer, autoimmune disorders, and nervous system conditions, leveraging the immunomodulatory effects of selective RXR and RAR agonists. Through its research, Io Therapeutics seeks to advance therapeutic options that can improve patient outcomes and enhance the understanding of RXR-related pathways in disease management.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

72 Patents

#85 in Houston, TX

#279 in Texas

#5,108 in US

#10,396 in the World

Houston, TX, United States of America

Io Therapeutics, Inc.

Forward Citations = 441

19 inventors:

Roshantha A Chandraratna (63 out of 291 patents)

Martin E Sanders (49 out of 51 patents)

Randolph J Noelle (11 out of 66 patents)

4. Ethan Dmitrovsky (11 out of 21 patents)

5. Elizabeth Nowak (11 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Io Therapeutics, Inc.. Retrieved from https://idiyas.com/company/io-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…